LPLP
CYTK icon

Lansdowne Partners Limited Partnership’s Cytokinetics CYTK Stock Holding History

Lansdowne Partners Limited Partnership’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		$22.1M Buy
2,321,865
+300,954
+15% +$2.72M 0.19% 33
2013
Q4 		$13.1M Hold
2,020,911
– – 0.11% 30
2013
Q3 		$15.3M Buy
2,020,911
+286,046
+16% +$3.07M 0.17% 26
2013
Q2 		$20.1M Buy
+1,734,865
New +$13.7M 0.25% 28

Other funds holding CYTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
SCM
Sigma Capital Management Stamford, Connecticut $1.95B AUM 42.86% 1-Year Est. Return

Lansdowne Partners Limited Partnership's CYTK Position: Q1 2014 in Review

Lansdowne Partners Limited Partnership increased its Cytokinetics (CYTK) stake by 15% in Q1 2014, buying an estimated $2.72M and bringing the position to 2,321,865 shares worth $22.1M. The position accounts for 0.19% of the portfolio, ranked #33.

Lansdowne Partners Limited Partnership first reported a position in CYTK in Q2 2013 and has held it in 4 quarters since. 109 funds tracked by Wall St. Rank hold CYTK as of Q1 2014.

  • Lansdowne Partners Limited Partnership held 2,321,865 shares of Cytokinetics worth $22.1M as of Q1 2014.
  • Lansdowne Partners Limited Partnership bought 300,954 Cytokinetics shares in Q1 2014, an estimated $2.72M.
  • Cytokinetics made up 0.19% of Lansdowne Partners Limited Partnership's portfolio in Q1 2014, its #33 holding.
  • Lansdowne Partners Limited Partnership first reported a position in Cytokinetics in Q2 2013 and has held it in 4 quarters since.
  • 109 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2014.

Based on Lansdowne Partners Limited Partnership's 13F filing for Q1 2014, filed 14 May 2014.